PepGen (NASDAQ:PEPG) Releases Earnings Results, Misses Expectations By $0.01 EPS

PepGen (NASDAQ:PEPG) issued its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01), FiscalAI reports.

Here are the key takeaways from PepGen’s conference call:

• PepGen reported a 46.5% mean improvement in splicing after four doses of PGN-EDODM1 at 10 mg/kg, with four of six treated participants exceeding 50% improvement. The company said this was the highest mean splicing correction reported to date in a multiple-dose DM1 study.
• The company also reported improvements across several functional measures: myotonia improved by 4.3 seconds at week 13, while hand grip strength improved 16% at week 16, alongside favorable changes in timed mobility tests. These results come from a small cohort and are early; patient-reported outcomes did not yet show a clear signal.
• Management described the treatment as generally well tolerated, with no serious adverse events, dose-limiting toxicities, or discontinuations. Four mild kidney-related events were reported; albuminuria was transient, and the company said it saw no meaningful changes in eGFR or serum creatinine.
• The U.S. multiple-ascending-dose study remains under a partial FDA clinical hold related to questions about prior mouse toxicology findings. PepGen said it is conducting additional mouse studies to address the agency’s concerns, although the hold has not stopped the ongoing study in other countries.
• PepGen expects to report longer-term safety data at 10 mg/kg and additional data from the open-label extension in January 2027, with results from the 12.5 mg/kg cohort expected in the first half of 2027. The company said these data will inform dose selection and discussions with regulators about a pivotal trial.

PepGen Stock Performance

Shares of NASDAQ:PEPG traded up $3.08 on Tuesday, hitting $5.46. The company’s stock had a trading volume of 78,048,120 shares, compared to its average volume of 1,366,822. The company has a market capitalization of $378.51 million, a price-to-earnings ratio of -4.25 and a beta of 2.02. PepGen has a 12 month low of $1.31 and a 12 month high of $7.80. The stock’s 50-day moving average is $2.66 and its two-hundred day moving average is $2.98.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings raised PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Finally, HC Wainwright reiterated a “buy” rating on shares of PepGen in a research report on Wednesday, September 9th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.40.

About PepGen

PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.